Midazolam Dosing for Seizures

Initial Dosing Recommendations

For a 45kg patient, the American Academy of Pediatrics recommends an initial dose of 0.05-0.10 mg/kg IV/IM, which equals 2.25-4.5 mg per dose, with a maximum of 4 mg per dose 1
Doses may be repeated every 10-15 minutes if needed for continued seizures, as recommended by the American Academy of Pediatrics 1
The American Academy of Pediatrics suggests monitoring oxygen saturation closely as there is an increased risk of apnea, especially when midazolam is combined with other sedative agents 1

For intravenous (IV) administration, the American Academy of Pediatrics recommends administering slowly over 2-3 minutes to avoid oversedation, and peak effect occurs at 3-5 minutes after administration 1
For patients with refractory status epilepticus, the American Academy of Pediatrics recommends a loading dose of 0.15-0.20 mg/kg (6.75-9 mg for a 45kg patient) may be followed by continuous infusion 1

If seizures continue despite bolus doses, the American Academy of Pediatrics recommends continuous infusion may be initiated at 1 μg/kg/min (0.06 mg/kg/hr) 1
The American Academy of Pediatrics suggests titrating by increments of 1 μg/kg/min every 15 minutes up to a maximum of 5 μg/kg/min (0.3 mg/kg/hr) until seizures stop 1

Patients with hepatic impairment may require dose reduction due to decreased clearance, as suggested by clinical guidelines 2

The American Academy of Pediatrics recommends being prepared to provide respiratory support regardless of administration route, and monitoring oxygen saturation continuously 1
The American Academy of Pediatrics suggests monitoring for hypotension, especially when administered rapidly, and using flumazenil to reverse life-threatening respiratory depression caused by midazolam 1

For ICU patients receiving continuous sedation, the European Society of Cardiology recommends using the minimum effective dose to avoid accumulation and delayed awakening 3
The European Society of Cardiology notes that midazolam has a shorter duration of action (1-4 hours) compared to other benzodiazepines, making it preferable for acute seizure management 3

The British Medical Association advises that midazolam is among the strongest independent risk factors for developing delirium in ICU settings 4
The British Medical Association suggests that for ICU patients, non-benzodiazepine sedatives (propofol, dexmedetomidine) have shown improved outcomes compared to benzodiazepines like midazolam 4